menu

Loading...

GNTA Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

1.040

Open

0.939

VWAP

0.99

Vol

21.22K

Mkt Cap

23.21M

Low

0.938

Amount

20.93K

EV/EBITDA(TTM)

--

Total Shares

23.43M

EV

7.05M

EV/OCF(TTM)

--

P/S(TTM)

--

Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.

Show More

Events Timeline

(ET)

2026-01-27

05:30:00

Genenta Science Plans to Acquire Majority Stake in ATC

2025-11-24 (ET)

2025-11-24

05:09:37

Genenta Science Offers Update on TEM-GBM Research Study

2025-10-24 (ET)

2025-10-24

05:06:19

Genenta Science and Anemocyte Form Partnership to Enhance Plasmid DNA Technology

2025-07-01 (ET)

2025-07-01

05:22:04

Genenta Science announces follow-up observations in glioblastoma study

2025-05-07 (ET)

2025-05-07

07:28:25

Genenta Science, Anemocyte announce collaboration

2025-03-19 (ET)

2025-03-19

09:31:57

Genenta Science announces EUR 20M financing to expand pipeline

2025-01-09 (ET)

2025-01-09

05:46:06

Genenta Science announces amendment to pact with AGC Biologics

2024-10-02 (ET)

2024-10-02

06:35:48

Genenta Science secures approval for trial for metastatic Renal Cell Cancer

News

Yahoo Finance

02-28Yahoo Finance

Genenta Science Shifts Focus to Defense Sector

Newsfilter

02-27Newsfilter

Genenta Science Transforms into Saentra Forge, Appoints New Board Member

Benzinga

Genenta Science Transitions to Defense Sector Consolidator

Benzinga

Biomx Inc Shares Surge After 13D Filing Reveals Major Stake

Yahoo Finance

01-27Yahoo Finance

Genenta Science Transforms into Defense Integrator with Strategic Acquisitions

Globenewswire

2025-12-19Globenewswire

Genenta CEO Pierluigi Paracchi Acquires 30,000 ADS, Holding Reaches 10% of Outstanding Shares

1 Analyst Rating

Wall Street analysts forecast GNTA stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

7.00

Averages

7.00

High

7.00

Current: 0.000

Low

7.00

Averages

7.00

High

7.00

No data

No data

Valuation Metrics

The current forward P/E ratio for Genenta Science SPA (GNTA.O) is -2.46, compared to its 5-year average forward P/E of -8.73. For a more detailed relative valuation and DCF analysis to assess Genenta Science SPA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-8.73

Current PE

-2.46

Overvalued PE

-3.05

Undervalued PE

-14.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-4.86

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.39

Undervalued EV/EBITDA

-10.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

25.80

Current PS

0.00

Overvalued PS

85.21

Undervalued PS

-33.61

Financials

AI Analysis

Annual

Quarterly

Whales Holding GNTA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Genenta Science SPA (GNTA) stock price today?

The current price of GNTA is 0.98 USD — it has decreased -1.11

What is Genenta Science SPA (GNTA)'s business?

Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.

What is the price predicton of GNTA Stock?

Wall Street analysts forecast GNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNTA is7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Genenta Science SPA (GNTA)'s revenue for the last quarter?

Genenta Science SPA revenue for the last quarter amounts to NaN USD, decreased

What is Genenta Science SPA (GNTA)'s earnings per share (EPS) for the last quarter?

Genenta Science SPA. EPS for the last quarter amounts to USD, decreased

How many employees does Genenta Science SPA (GNTA). have?

Genenta Science SPA (GNTA) has 13 emplpoyees as of March 02 2026.

What is Genenta Science SPA (GNTA) market cap?

Today GNTA has the market capitalization of 23.21M USD.